Bevacizumab

Manufactured by Selleck Chemicals

Sourced in United States

Bevacizumab is a monoclonal antibody that binds to and inhibits the vascular endothelial growth factor (VEGF). It is used in the production and research of pharmaceuticals.

Automatically generated - may contain errors

Lab products found in correlation

16 protocols using bevacizumab

Comparative Study of Anticancer Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lactic acid (No. W261114-1KG-K), isopropanol (No. I9516-25ML), cinnamic aldehyde (No. W228613-100G-K), 1-chloro-2,4- dinitrobenzene (DNCB) (No. 237329-10G), 6-methylcoumarin (No. W269905-100G-K), and nickel sulfate (No. N4882-1KG) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sunitinib (No. S7781), bevacizumab (No. A2006), palbociclib (No. S1116), imatinib (No. S2475), olaparib (No. S1060), dasatinib (No. S1021), nilotinib (No. S1033), bevacizumab (No. A2006), sorafenib (No. S7397), and regorafenib (No. S1178) were obtained from Selleckchem. Paclitaxel (No. HY-B0015) was purchased from MedChemExpress, Monmouth Junction, NJ, USA. Cysteine peptide (Ac-RFAAKAA-COOH) was purchased from Genosphere Biotechnologies, Paris, France. Peptide stock solutions were prepared to a final concentration of 0.667 mM in 100 mM phosphate buffer (pH of 7.5).

Roger I., Montero P., García A., Milara J., Ribera P., Pérez-Fidalgo J.A, & Cortijo J. (2022). Evaluation of Antineoplastic Delayed-Type Hypersensitivity Skin Reactions In Vitro. Pharmaceuticals, 15(9), 1111.

+ Open protocol

+ Expand

Modulation of P2Y11 Receptor Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols

The slowly hydrolyzable ATP analog ATPγS [7 (link), 20 (link)] (Sigma Aldrich, St. Louis, MO, USA) as well as the suramin analog NF340 [7 (link), 10 (link), 13 (link), 21 (link)] (Santa Cruz, Dallas, TX, USA) served as P2Y₁₁ receptor agonist (20 µM) and antagonist (20 µM), respectively. Further reagents utilized in this study include the PDE4-selective inhibitor rolipram (10 µM) (Sigma-Aldrich), BAPTA-AM (10 µM) (Sigma-Aldrich), calphostin C (250 nM) (Tocris), recombinant IL-1α and IL-1β (0.5–2 ng·ml⁻¹) (R&D Systems, Minneapolis, MN, USA), the TACE/ADAM17 inhibitor TAPI-1 (20 µM) (Tocris), the selective inhibitor of Epac1 (R)-CE3F4 (20 µM) (Tocris), and the humanized anti-VEGF monoclonal antibody bevacizumab (0.5 µg ml⁻¹) (Selleckchem, Houston, TX, USA).

Klaver D., Gander H., Dobler G., Rahm A, & Thurnher M. (2022). The P2Y11 receptor of human M2 macrophages activates canonical and IL-1 receptor signaling to translate the extracellular danger signal ATP into anti-inflammatory and pro-angiogenic responses. Cellular and Molecular Life Sciences, 79(10), 519.

+ Open protocol

+ Expand

Metabolic Effects on Human Retinal Cells

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

O-phosphorylethanolamine (Sigma, USA, #P0503-1G), hyodeoxycholic acid (Sigma, USA, H3878-5G), L-tryptophanamide (Selleck, USA, #S6155), cyclamic acid (Yuanye Biology, China, #S70017-5G), sodium cyclamate (Sigma, USA, #47827), curcumin [65 (link)] (Selleck, USA, #S1848), bevacizumab (Selleck, USA, #A2006). Blank control group (culture medium), negative control (0.1% DMSO group), curcumin (positive control group when studying the effect of differential metabolites on HRPECs), bevacizumab group (positive control group when studying the effect of differential metabolites on HRECs) were set.

Deng Y., Shuai P., Wang H., Zhang S., Li J., Du M., Huang P., Qu C, & Huang L. (2021). Untargeted metabolomics for uncovering plasma biological markers of wet age-related macular degeneration. Aging (Albany NY), 13(10), 13968-14000.

+ Open protocol

+ Expand

Bevacizumab Treatment for Traumatic Brain Injury

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the TBI + Beva group, bevacizumab (10 mg/kg, in saline solution; Selleck Chemicals) was intraperitoneally injected once immediately after TBI (16 (link),20 (link)). The TBI + Vehicle group animals were intraperitoneally administered equal amounts of saline.

Wu M., Gong Y., Jiang L., Zhang M., Gu H., Shen H, & Dang B. (2022). VEGF regulates the blood‑brain barrier through MMP‑9 in a rat model of traumatic brain injury. Experimental and Therapeutic Medicine, 24(6), 728.

+ Open protocol

+ Expand

Quantifying VEGF-Driven Angiogenesis in Liver Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

To examine the role of vascular endothelial growth factor (VEGF) in angiogenic
activity in CMs of BEL7402/Huh7 cells, we collected the CMs from different
groups as follows: (1) Huh7 NC/CLIC1-knockdown, (2) Huh7 NC/CLIC1
overexpression, (3) Huh7 CLIC1 overexpression + AntiVEGF (Bevacizumab) (A2006,
Selleck Chemicals), (4) BEL7402 NC/CLIC1-knockdown, (5) BEL7402 NC/CLIC1
overexpression, and (6) BEL7402 CLIC1 overexpression + AntiVEGF. The levels of
VEGFA were measured using an ELISA kit (ELH-VEGF-CL, Raybiotech) according to
the manufacturer's instructions.
For the EA.hy926 migration assay, 4 × 10⁴ EA.hy926 cells were seeded
in the upper chamber with FBS-free media, and 4 × 10⁴ HCC cells
(Huh7/BEL7402) or CMs of HCC cells were placed in the lower chamber of a 24-well
transwell plate (8 μm, Corning). After 24 h of incubation at 37°C and 5%
CO₂, the cells were fixed with methanol and stained with 0.5%
crystal violet. Cells on the upper surface were removed with cotton swabs, and
cells that migrated to the lower surface were counted under an optical
microscope. The experiment was repeated 3 times.

Wei X., Pan B., Yang M., Shu W., Khan A.R., Su R., Lin H, & Xu X. (2022). CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA. Technology in Cancer Research & Treatment, 21, 15330338221106820.

+ Open protocol

+ Expand

Tumor Sphere Drug Sensitivity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

One hundred CR cells in 100 µl of complete F-medium were seeded in ultra-low attachment 96-well plates (Corning) to generate tumorspheres. The tumorspheres were treated with DMSO, 4-OH-tamoxifen (Sigma-Aldrich), doxorubicin (WAKO), docetaxel (WAKO), paclitaxel (WAKO), bevacizumab (Selleck), fulvestrant (Selleck) or palbociclib (Selleck) and incubated at 37 °C in 5% CO₂. After 48 h of treatment, the CellTiter-Glo® 3D cell viability assay (Promega, WI, USA) was used to assess growth inhibition. To determine the IC50, cells were treated for 4 days with 4-OH-tamoxifen. was also used for drug sensitivity assay.

Mimoto R., Yogosawa S., Saijo H., Fushimi A., Nogi H., Asakura T., Yoshida K, & Takeyama H. (2019). Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells. Scientific Reports, 9, 13405.

+ Open protocol

+ Expand

Growth Curves of Cell Lines with Cytokines

Check if the same lab product or an alternative is used in the 5 most similar protocols

For growth curves, cell lines were counted using trypan blue and passaged every 2 days, seeding cells at the original concentration. Cells were grown with 10 ng/ml IL-5 (Peprotech), 50 ng/ml VEGF-165 (Peprotech), 10 µg/ml Bevacizumab (Selleckchem) and/or 500 pg/ml Benralizumab (AstraZeneca). Where appropriate, doxycycline induction of transduced cells was at 2 µg/ml. Growth curves were not performed in the PDX, instead the cells were just counted at day 6 after seeding.

Kellaway S.G., Potluri S., Keane P., Blair H.J., Ames L., Worker A., Chin P.S., Ptasinska A., Derevyanko P.K., Adamo A., Coleman D.J., Khan N., Assi S.A., Krippner-Heidenreich A., Raghavan M., Cockerill P.N., Heidenreich O, & Bonifer C. (2024). Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nature Communications, 15, 1359.

+ Open protocol

+ Expand

Chick Embryo Tumor Sphere Xenograft Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Axitinib was purchased from SelleckChem (Houston, TX). Axitinib was diluted in DMSO and stored at −20 °C at a stock concentration of 10 mM. Chick embryo tumor sphere xenografts were treated topically with either 30µL Axitinib (10 µM) or control (DMSO) on Day 4 and Day 7 post-engraftment. Tumor growth was monitored using IVIS imaging and at end-point, Day 9 post-engraftment, tumors were resected, fixed and processed for immunohistochemistry. Similarly, Bevacizumab was also purchased from SelleckChem (Houston, TX). Chicken embryo spheres were treated with 10.5µL of Bevacizumab (7.5 mg/kg) or control on Day 4 and 7 post engraftment and tumor growth was monitored through IVIS.

Javed S., Soukhtehzari S., Fernandes N, & Williams K.C. (2022). Longitudinal bioluminescence imaging to monitor breast tumor growth and treatment response using the chick chorioallantoic membrane model. Scientific Reports, 12, 17192.

+ Open protocol

+ Expand

Endothelial Cell Network Formation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Matrigel gels were created using low growth factor Matrigel (Corning, Corning) (protein concentration >9.5 mg/mL) in a 48 well plate. It was gelled at 37°C overnight, then rinsed twice with PBS. ECs were added in 250 μL EBM with no supplement and allowed to adhere for 1 hour. An additional 250 μL of 48 hour conditioned medium from unaffected or affected fibroblasts, or non-conditioned medium with or without 20 ng/mL VEGF and with or without 250 μL/mL bevacizumab (Anti-VEGF monoclonal antibody, Selleckchem) in 5% FBS + 1% Penicillin/Streptomycin in DMEM were added and ECs were incubated for 14 hours before being fixed and stained for CD31 as described above. Endothelial cell network formation was also tracked by live-cell imaging via Celigo Imaging Cytomenter (Nexcelom Biosciences) at 2, 4, 8, 16, and 24 hours.

Hurley-Novatny A.C., Allbritton-King J.D., Jha S., Cowen E.W., Colbert R.A., Navid F, & Bhattacharyya T. (2022). Fibroblasts from Melorheostosis Patients Promote Angiogenesis in Healthy Endothelial Cells through Secreted Factors. The Journal of investigative dermatology, 142(9), 2406-2414.e5.

+ Open protocol

+ Expand

Evaluating Combination Therapy Efficacy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Gefinitib, cediranib, bevacizumab, and paclitaxel were purchased from Selleck Chemicals, LLC (Houston, TX, USA) and suspended in DMSO.

Bi J., Dixit G., Zhang Y., Devor E.J., Losh H.A., Newtson A.M., Coleman K.L., Santillan D.A., Maretzky T., Thiel K.W, & Leslie K.K. (2021). Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. Pharmaceuticals, 14(7), 682.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!